Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer
- PMID: 20332495
- DOI: 10.2146/ajhp100078
Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer
Abstract
Purpose: To discuss trends in breast and prostate cancer prevalence and survival; risk factors for bone loss, osteoporosis, and fractures and the approach to risk assessment in patients with these malignancies; established and investigational drug therapies for managing cancer treatment-induced bone loss and osteoporosis; and the role of health-system pharmacists in promoting bone health in patients with breast or prostate cancer.
Summary: Breast cancer and prostate cancer are common, deadly diseases, but many survivors are alive today because of improvements in early detection and treatment over the past 10-15 years. Cancer chemotherapy, corticosteroids, hormone-ablation therapy, and other common risk factors place patients with breast or prostate cancer at high risk for bone loss, osteoporosis, and fractures. Most patients with breast or prostate cancer should undergo assessment of risk for bone loss and osteoporosis that involves a bone-related history and physical examination, dual-energy X-ray absorptiometry scanning, and the FRAX fracture risk assessment tool from the World Health Organization. A recent National Comprehensive Cancer Network task force report on bone health in cancer care provides recommendations for considering the use of pharmacologic therapy on the basis of the results of this assessment. Bisphosphonates are useful for slowing or preventing bone loss associated with hormone-ablation therapy in women with breast cancer and men with prostate cancer, although fracture data are limited in women and not available in men. The usefulness of other therapies (selective estrogen receptor modulators, teriparatide, calcitonin salmon, and estrogens) is limited by adverse effects, a lack of experience with the drugs in these patient populations, or both. Various drug therapies are in development for managing cancer treatment-induced bone loss and osteoporosis. The agent closest to approval by the Food and Drug Administration, denosumab, has been shown to improve bone mineral density in women and men receiving hormone-ablation therapy for breast or prostate cancer, but additional data are needed to dispel safety concerns that could limit the use of this drug in these patient populations. Health-system pharmacists play an important role in screening patients with a history of breast or prostate cancer for bone loss or osteoporosis, making drug therapy recommendations to address the problem, and counseling patients on modifiable risk factors for osteoporosis and proper use of drug therapies to improve bone health.
Conclusion: Health-system pharmacists can improve the detection and management of cancer treatment-induced bone loss and osteoporosis in patients receiving systemic therapy for breast or prostate cancer.
Similar articles
-
Early breast and prostate cancer and clinical outcomes (fracture).Oncology (Williston Park). 2009 Dec;23(14 Suppl 5):16-20. Oncology (Williston Park). 2009. PMID: 20128324
-
Bone health management in prostate cancer patients receiving androgen deprivation therapy.J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1. J Oncol Pharm Pract. 2012. PMID: 21807761
-
Management of bone loss due to endocrine therapy during cancer treatment.Osteoporos Int. 2023 Apr;34(4):671-680. doi: 10.1007/s00198-023-06672-3. Epub 2023 Jan 19. Osteoporos Int. 2023. PMID: 36656338 Review.
-
Background to and management of treatment-related bone loss in prostate cancer.Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002. Drugs Aging. 2002. PMID: 12495366 Review.
-
Improving osteoporosis screening, risk assessment, diagnosis, and treatment initiation: role of the health-system pharmacist in closing the gap.Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 3):S4-8. doi: 10.2146/ajhp100075. Am J Health Syst Pharm. 2010. PMID: 20332497
Cited by
-
A study to evaluate the cause of bone demineralization in gynecological cancer survivors.Oncologist. 2013;18(4):423-9. doi: 10.1634/theoncologist.2012-0416. Epub 2013 Jan 30. Oncologist. 2013. PMID: 23363808 Free PMC article.
-
The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.Support Care Cancer. 2014 Sep;22(9):2409-15. doi: 10.1007/s00520-014-2183-6. Epub 2014 Apr 3. Support Care Cancer. 2014. PMID: 24696083
-
Cancer-associated bone disease.Osteoporos Int. 2013 Dec;24(12):2929-53. doi: 10.1007/s00198-013-2530-3. Epub 2013 Oct 22. Osteoporos Int. 2013. PMID: 24146095 Free PMC article. Review.
-
Therapy-Induced Senescence Drives Bone Loss.Cancer Res. 2020 Mar 1;80(5):1171-1182. doi: 10.1158/0008-5472.CAN-19-2348. Epub 2020 Jan 13. Cancer Res. 2020. PMID: 31932453 Free PMC article.
-
Pharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectives.J Pharm Health Care Sci. 2015 Jan 28;1:2. doi: 10.1186/s40780-014-0001-4. eCollection 2015. J Pharm Health Care Sci. 2015. PMID: 26819713 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous